The company maintains a conservative capital structure with a debt-to-equity ratio of 0.04 as of 2026Q1, providing a stable foundation despite the $120.7 million in goodwill that warrants ongoing monitoring.
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 |
|---|
| Total Current Assets | 731.58M | 644.18M | 686.07M | 493.11M | 734.15M | 601.59M | 630.42M | 472.64M | 493.49M | 228.45M | 151.4M | 105.98M | 108.89M | 97.16M | 91.74M | 49.4M | 39.81M | 72.88M | 69.46M |
| Cash & Short-Term Investments | 384.24M | 308.67M | 453.61M | 254.87M | 461.33M | 339.68M | 422.53M | 347.07M | 356.02M | 140.04M | 90.12M | 62.19M | 74.34M | 82.19M | 88.51M | 48.54M | 32.7M | 66.52M | 60.38M |
| Cash Only | 184.87M | 128.45M | 69.33M | 75.05M | 93.12M | 203.43M | 288.64M | 181.38M | 192.25M | 100.3M | 90.12M | 62.19M | 74.34M | 82.19M | 88.51M | 48.54M | 23.74M | 31.41M | 52.88M |
| Short-Term Investments | 199.37M | 180.22M | 384.28M | 179.82M | 368.21M | 136.25M | 133.89M | 165.69M | 163.77M | 39.74M | 0 | 0 | 0 | 0 | 0 | 0 | 8.96M | 35.12M | 7.5M |
| Accounts Receivable | 182.18M | 187.8M | 142.08M | 144.16M | 165.5M | 148.93M | 140.88M | 87.33M | 102.92M | 65.59M | 41.53M | 25.91M | 17.27M | 5.05M | 675K | 0 | 158K | 3.74M | 2.28M |
| Days Sales Outstanding | 80.12 | 95.34 | 78.36 | 86.61 | 90.53 | 93.76 | 98.81 | 81.16 | 91.87 | 79.21 | 70.5 | 65.48 | 51.65 | 153.48 | 166.47 | - | 544.06 | 36.01 | 93.47 |
| Inventory | 87.06M | 82.39M | 54.29M | 77.41M | 91.54M | 85.96M | 48.33M | 26.63M | 25.66M | 16.3M | 16.8M | 12.59M | 13.44M | 7.15M | 1.15M | 389K | 6.75M | 2.35M | 6.55M |
| Days Inventory Outstanding | 325.15 | 403.3 | 254.37 | 337.24 | 383.08 | 417.99 | 336.24 | 583.39 | 609.89 | 391.12 | 511.63 | 545.44 | 852.03 | 2.36K | - | - | -183.94 | -99.75 | 1000K |
| Other Current Assets | 78.09M | 65.33M | 36.09M | 16.68M | 15.78M | 0 | 0 | 0 | 8.89M | 6.52M | 2.96M | 0 | 3.85M | 0 | 144K | 0 | 6.75M | 0 | 0 |
| Total Non-Current Assets | 769.14M | 808.47M | 682M | 784.56M | 968.36M | 1.09B | 873.68M | 687.64M | 484.32M | 196.01M | 158.16M | 82.75M | 28.62M | 13.83M | 2.25M | 4.33M | 7.2M | 7.02M | 7.68M |
| Property, Plant & Equipment | 10.04M | 10.53M | 11.54M | 13.53M | 15.17M | 16.95M | 37.82M | 17.07M | 4.09M | 5.12M | 4.34M | 3.87M | 2.45M | 2.55M | 1.42M | 1.31M | 1.25M | 1.86M | 1.99M |
| Fixed Asset Turnover | 73.51x | 68.27x | 57.32x | 44.90x | 43.98x | 34.19x | 13.76x | 23.01x | 99.85x | 58.98x | 49.49x | 37.28x | 49.85x | 4.71x | 1.04x | 0.61x | 0.08x | 20.40x | 4.47x |
| Goodwill | 120.67M | 124.88M | 117.02M | 117.02M | 117.02M | 117.52M | 77.91M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 549.71M | 569.46M | 521.91M | 599.89M | 702.46M | 784.69M | 364.34M | 24.84M | 31.37M | 36.02M | 16.49M | 976K | 5.43M | 1.16M | 683K | 912K | 1.14M | 1.37M | 1.6M |
| Long-Term Investments | 0 | 0 | 0 | 16.62M | 93.9M | 119.17M | 350.36M | 591.77M | 418.8M | 133.64M | 75.41M | 55.01M | 19.82M | 8.76M | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 57.9M | 65.25M | 31.53M | 37.51M | 39.81M | 49.23M | 43.25M | 21.89M | 380K | 389K | 20.19M | 391K | 6.35M | 1.52M | 144K | 2.11M | 4.8M | 3.79M | 4.09M |
| Total Assets | 1.5B | 1.45B | 1.37B | 1.28B | 1.7B | 1.69B | 1.5B | 1.16B | 977.81M | 424.46M | 309.57M | 188.73M | 137.51M | 111M | 93.99M | 53.73M | 47.01M | 79.9M | 77.13M |
| Asset Turnover | 0.54x | 0.49x | 0.48x | 0.48x | 0.39x | 0.34x | 0.35x | 0.34x | 0.42x | 0.71x | 0.69x | 0.77x | 0.89x | 0.11x | 0.02x | 0.01x | 0.00x | 0.47x | 0.12x |
| Asset Growth % | 28.37% | 6.18% | 7.08% | -24.95% | 0.79% | 12.3% | 29.63% | 18.66% | 130.36% | 37.11% | 64.03% | 37.25% | 23.89% | 18.09% | 74.93% | 14.3% | -41.16% | 3.58% | - |
| Total Current Liabilities | 373.93M | 338.17M | 292.4M | 290.2M | 687.96M | 315.38M | 245.11M | 160.59M | 161.35M | 123M | 80.74M | 56.1M | 27.49M | 26.4M | 22.98M | 18.77M | 15.21M | 10.03M | 8.27M |
| Accounts Payable | 0 | 2.68M | 4.59M | 1.96M | 10.54M | 9.33M | 6.15M | 10.14M | 3.19M | 6.84M | 8.05M | 4.31M | 1.86M | 3.14M | 2.81M | 10.08M | 11.26M | 6.25M | 4.47M |
| Days Payables Outstanding | 132.68 | 13.1 | 21.49 | 8.56 | 44.12 | 45.37 | 42.77 | 222.18 | 75.94 | 164.18 | 245.29 | 186.94 | 118.1 | 1.04K | - | - | -306.7 | -265.42 | 1000K |
| Short-Term Debt | 0 | 0 | 0 | 0 | 401.97M | 0 | 0 | 0 | 2.18M | 4.28M | 0 | 497K | 0 | 0 | 11.81M | 6.78M | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2.18M | 287K | 209K | 176K | 143K | 8.09M | 508K | 232K | 0 | 0 | 0 |
| Other Current Liabilities | 373.93M | 98.72M | 68.56M | 77.08M | 54.95M | 93.04M | 55.99M | 14.47M | 22.99M | 17.03M | 63.33M | 26.79M | 19.7M | 10.16M | 7.86M | 1.55M | 2.5M | 1.29M | 2.5M |
| Current Ratio | 1.96x | 1.90x | 2.35x | 1.70x | 1.07x | 1.91x | 2.57x | 2.94x | 3.06x | 1.86x | 1.88x | 1.89x | 3.96x | 3.68x | 3.99x | 2.63x | 2.62x | 7.26x | 8.39x |
| Quick Ratio | 1.72x | 1.66x | 2.16x | 1.43x | 0.93x | 1.63x | 2.37x | 2.78x | 2.90x | 1.72x | 1.67x | 1.66x | 3.47x | 3.41x | 3.94x | 2.61x | 2.17x | 7.03x | 7.60x |
| Cash Conversion Cycle | 272.59 | 485.53 | 311.24 | 415.3 | 429.49 | 466.38 | 392.28 | 442.37 | 625.82 | 306.15 | 336.83 | 423.98 | 785.58 | 1.48K | - | - | 666.81 | 201.68 | 1000K |
| Total Non-Current Liabilities | 49.99M | 52.76M | 39.94M | 65.96M | 128.35M | 557.92M | 514.14M | 404.27M | 363.44M | 33.98M | 37.07M | 13.76M | 38.66M | 51.13M | 13.44M | 25.52M | 76.12M | 76.02M | 75.61M |
| Long-Term Debt | 30.27M | 0 | 0 | 0 | 0 | 379.25M | 361.75M | 345.17M | 329.46M | 22.26M | 4.17M | 7.08M | 26.95M | 34.39M | 11.09M | 22.71M | 75M | 75M | 75M |
| Capital Lease Obligations | 86.17M | 30.36M | 27.38M | 33.2M | 36M | 41.3M | 48.81M | 30.44M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -942K | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 4.96M | 24.96M | 49.81M | 85.36M | 35.22M | 0 | 31.46M | 14.96M | 114K | 854K | 6.56M | 12.64M | -309K | 942K | 0 | 0 | -75M |
| Other Non-Current Liabilities | 19.72M | 22.4M | 7.6M | 7.8M | 42.54M | 52.02M | 68.36M | 28.66M | 33.97M | 10.58M | 31.41M | 35.21M | 10.44M | 15.32M | 2.04M | 1.4M | 1.12M | 1.02M | 169.62K |
| Total Liabilities | 423.92M | 390.93M | 332.34M | 356.16M | 816.3M | 873.3M | 759.24M | 564.85M | 524.79M | 156.98M | 117.81M | 69.86M | 66.15M | 77.53M | 36.42M | 44.29M | 91.33M | 86.06M | 83.88M |
| Total Debt | 30.27M | 40.98M | 34.27M | 41.53M | 444.76M | 427.03M | 414.32M | 378.44M | 329.46M | 26.54M | 4.17M | 7.19M | 26.95M | 34.39M | 22.9M | 29.49M | 75M | 75M | 75M |
| Net Debt | -154.6M | -87.47M | -35.06M | -33.53M | 351.64M | 223.59M | 125.69M | 197.05M | 137.21M | -73.76M | -85.96M | -55M | -47.39M | -47.8M | -65.61M | -19.06M | 51.26M | 43.59M | 22.12M |
| Debt / Equity | 0.03x | 0.04x | 0.03x | 0.05x | 0.50x | 0.52x | 0.56x | 0.64x | 0.73x | 0.10x | 0.02x | 0.06x | 0.38x | 1.03x | 0.40x | 3.12x | - | - | - |
| Debt / EBITDA | 1.06x | 0.75x | 0.21x | 0.52x | 3.38x | 3.60x | 2.16x | 2.38x | 2.17x | 0.25x | 0.07x | 0.39x | 1.07x | - | - | - | - | 14.74x | - |
| Net Debt / EBITDA | -5.41x | -1.60x | -0.22x | -0.42x | 2.67x | 1.88x | 0.66x | 1.24x | 0.91x | -0.69x | -1.52x | -2.96x | -1.88x | - | - | - | - | 8.57x | - |
| Interest Coverage | - | - | - | 2.15x | 9.59x | 4.12x | 8.10x | 7.50x | 7.98x | 63.48x | 10.65x | 4.37x | 4.42x | -10.76x | -11.95x | -20.15x | - | - | -2.86x |
| Total Equity | 1.08B | 1.06B | 1.04B | 921.52M | 886.2M | 815.85M | 744.86M | 595.43M | 453.02M | 267.48M | 191.75M | 118.88M | 71.35M | 33.46M | 57.57M | 9.44M | -44.32M | -6.16M | -6.75M |
| Equity Growth % | 22.32% | 2.51% | 12.39% | 3.98% | 8.62% | 9.53% | 25.1% | 31.43% | 69.37% | 39.49% | 61.31% | 66.6% | 113.23% | -41.87% | 509.66% | 121.31% | -619.95% | 8.76% | - |
| Book Value per Share | 18.68 | 18.81 | 18.51 | 16.60 | 14.37 | 15.01 | 13.87 | 11.06 | 8.37 | 5.02 | 3.71 | 2.32 | 1.41 | 1.05 | 3.30 | 0.68 | -3.20 | -0.44 | -0.49 |
| Total Shareholders' Equity | 1.08B | 1.06B | 1.04B | 921.52M | 886.2M | 815.85M | 744.86M | 595.43M | 453.02M | 267.48M | 191.75M | 118.88M | 71.35M | 33.46M | 57.57M | 9.44M | -44.32M | -6.16M | -6.75M |
| Common Stock | 58K | 57K | 56K | 55K | 54K | 53K | 53K | 53K | 52K | 51K | 50K | 49K | 43K | 40K | 31K | 14K | 2K | 6K | 5.52K |
| Retained Earnings | 515.58M | 517.88M | 556.43M | 482.56M | 481.25M | 379.92M | 326.5M | 199.55M | 86.49M | -26.82M | -84.29M | -144.64M | -158.66M | -178.53M | -86.25M | -39.97M | -93.79M | -55.32M | -55.78M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -255K | -44K | -189K | -593K | -3.21M | 1.54M | 8.97M | 7.42M | -3.16M | -747K | -134K | -488K | -154K | 0 | -57K | 1K | 0 | 2K | -2.15M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Regulatory and generic erosion
As reported in recent financial statements, Supernus has maintained a stable total asset base of approximately $1.5 billion through 2026Q1, signaling that the company is successfully preserving its core capital structure despite the ongoing revenue volatility associated with its CNS product portfolio transition and generic competition.
The consistency in total assets suggests that management has avoided significant asset impairment or fire-sale liquidations during the current period of commercial reinvestment. Investors should monitor whether this stability persists as the company continues to navigate the regulatory hurdles surrounding its pipeline candidates.
Based on reported figures, Supernus maintains a conservative capital structure with a debt-to-equity ratio of 0.04 as of 2026Q1, which indicates that the company is not reliant on external financing to fund its current high-cost commercialization efforts for the Qelbree ADHD franchise.
This negligible debt load provides a significant buffer against interest rate volatility and allows the company to prioritize R&D and marketing spend without the pressure of debt service obligations. Such a pristine balance sheet appears to be a strategic choice, offering the firm optionality to pursue future bolt-on acquisitions.
According to recent SEC filings, the company's current ratio of 1.96 in 2026Q1 demonstrates a healthy liquidity position, providing a sufficient buffer to cover short-term obligations while the firm continues to absorb the cash-intensive launch costs associated with its newer CNS product offerings.
The improvement in cash reserves from $69.3 million in 2024Q4 to $184.9 million in 2026Q1 suggests that the company is successfully managing its working capital to bolster its defensive position. This liquidity profile appears adequate to sustain operations through potential regulatory delays in the Parkinson's franchise.
As indicated by quarterly data, equity has expanded to $1.1 billion by 2026Q1, primarily supported by a cumulative retained earnings balance of $515.6 million, which reflects the historical profitability of the legacy epilepsy portfolio despite recent margin pressures from new product launch investments.
The steady accumulation of retained earnings suggests that the business model remains fundamentally capable of generating value, even if current GAAP earnings are temporarily depressed by high SG&A. Investors should watch for whether this equity base continues to grow as the ADHD segment achieves greater operating scale.
Based on the provided balance sheet, the $120.7 million in goodwill as of 2026Q1 warrants careful monitoring, as any failure to meet long-term growth targets for acquired assets could necessitate future impairment charges that would negatively impact the company's currently healthy equity position.
While the current goodwill level appears manageable relative to total assets, it represents a potential vulnerability if the commercial performance of acquired CNS assets fails to meet management's internal projections. This risk is particularly relevant given the regulatory setbacks that have historically plagued the company's drug-device combination pipeline.
Quick answers to the most common questions about buying SUPN stock.
As of 2025, Supernus Pharmaceuticals, Inc. (SUPN) had total assets of $1.45B including $644.2M in current assets.
Supernus Pharmaceuticals, Inc. (SUPN) carries total debt of $41.0M, offset by $308.7M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Supernus Pharmaceuticals, Inc. (SUPN) has total shareholders' equity (book value) of $1.06B ($18.81 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Supernus Pharmaceuticals, Inc. (SUPN) reported a current ratio of 1.90x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.